Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Naproxen (ATC: M01AE02) innerhalb des Zeitraumes vom 01.10.2026 bis zum 30.09.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient Naproxen (ATC: M01AE02), AOK Niedersachsen. The health insurance fund offers rebate contracts to all interested pharmaceutical companies without a selection decision for the period until the entry into force of exclusive contracts following a formal award procedure according to the regulations of Part 4 of the GWB. The contract conclusions take place within the framework of an "open-house model" and serve as a bridge between the start of generic competition (patent expiry) and the awarding of exclusive contracts. The offered contracts are non-exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions, and access procedures are uniform – individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, with the earliest contract start being 01.10.2026. All contracts end at the latest on 30.09.2028, regardless of the date of the respective contract conclusion. Joining or concluding a contract can take place within the twenty-four-month period on the first day of…

TENDER BRIEF

TENDER DOCUMENTS